<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054400</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1030</org_study_id>
    <nct_id>NCT05054400</nct_id>
  </id_info>
  <brief_title>Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR</brief_title>
  <official_title>Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relationship between brain malignancy volume as&#xD;
      defined by post-contrast T1 weighted and F18 Fluciclovine before and following LITT. We&#xD;
      hypothesize that imaging with F18 Fluciclovine will be superior to anatomic MR imaging in&#xD;
      lesion volume assessment before treatment and that residual F18 Fluciclovine defined tumor&#xD;
      will predict local post-LITT disease recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives&#xD;
&#xD;
      -To estimate the accuracy of F18 Fluciclovine PET MR for laser interstitial thermal therapy&#xD;
      (LITT) treatment response assessment as determined by T1 post-contrast MR brain imaging.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  To assess changes in F18 Fluciclovine defined disease with LITT.&#xD;
&#xD;
        -  To assess the volume change of the idealized quantitative T1 values of lesions compared&#xD;
           -To assess the volume change of idealized quantitative T2 values of lesions compared to&#xD;
           -Chemical Exchange Saturation Transfer (CEST) MRI - To assess the ability of CEST&#xD;
           imaging to differentiate treatment change from residual disease in brain malignancy&#xD;
           following LITT.&#xD;
&#xD;
        -  Multiple B Value Diffusion Imaging (Adv Diff) - To assess whether Adv Diff can&#xD;
           differentiate treatment changes from residual disease in brain malignancy following&#xD;
           LITT.&#xD;
&#xD;
        -  Gradient- and Spin-Echo DSC perfusion imaging - To assess whether GESE DSC improves&#xD;
           differentiation of treatment change from residual disease in brain malignancy -Adv ASL&#xD;
           perfusion imaging - To assess the ability of Adv ASL to differentiate treatment change&#xD;
           from residual disease in brain malignancy following radiation therapy.&#xD;
&#xD;
        -  Exploratory Objectives&#xD;
&#xD;
        -  To assess the relationship between post-LITT enhancing brain tissue and F18 -To assess&#xD;
           changes in regional homogeneity (ReHo) values after LITT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the relationship between brain malignancy volume as defined by post-contrast T1 weighted and F18 Fluciclovine before and following LITT.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Cancer</condition>
  <condition>Gliomas</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>F18 Fluciclovine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>radioactive imaging agent help researchers better &quot;see&quot; how the disease is responding to laser interstitial thermal therapy (LITT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F18 Fluciclovine</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>F18 Fluciclovine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>F18 Fluciclovine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  An adult patient with suspected or pathology-proven central nervous system neoplasm.&#xD;
&#xD;
          -  MRI of the brain, positive for at least one intra-axial lesion greater than 5 mm.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Contraindication to MR imaging.&#xD;
&#xD;
          -  Known allergy to gadolinium-based contrast agents.&#xD;
&#xD;
          -  Renal failure as defined by a GFR less than 30 or the use of hemodialysis.&#xD;
&#xD;
          -  Pregnant.&#xD;
&#xD;
          -  Patients less than 18 years of age will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Johnson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Johnson</last_name>
    <phone>(713) 792-8443</phone>
    <email>jjohnson12@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77031</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jason M Johnson</last_name>
    </contact>
    <investigator>
      <last_name>Jason M Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

